STOCK TITAN

[S-8] Zimmer Biomet Holdings, Inc. Employee Benefit Plan Registration

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

Zimmer Biomet Holdings has filed a Form S-8 to register securities under its 2009 Stock Incentive Plan. The company, a large accelerated filer headquartered in Warsaw, Indiana, is registering additional shares for employee benefits.

Key aspects of the filing include:

  • Registration covers the amended and restated 2009 Stock Incentive Plan (referenced in 8-K filed June 3, 2025)
  • Filing incorporates by reference several documents including the Annual Report for FY2024, Quarterly Report for Q1 2025, and proxy materials
  • Includes comprehensive indemnification provisions for directors and officers under Delaware law
  • Company maintains directors' and officers' liability insurance coverage

The filing includes standard undertakings regarding post-effective amendments and removal of unsold securities. Legal opinion and consent from PricewaterhouseCoopers LLP are filed as exhibits. This registration statement enables Zimmer Biomet to offer equity-based compensation to employees under its incentive plan.

Zimmer Biomet Holdings ha presentato un Modulo S-8 per registrare titoli nell'ambito del suo Piano di Incentivi Azionari 2009. L'azienda, un grande emittente accelerato con sede a Warsaw, Indiana, sta registrando azioni aggiuntive per benefici destinati ai dipendenti.

Gli aspetti principali della registrazione includono:

  • La registrazione riguarda il Piano di Incentivi Azionari 2009 modificato e aggiornato (citato nel modulo 8-K presentato il 3 giugno 2025)
  • La documentazione fa riferimento a vari documenti, tra cui il Rapporto Annuale per l'anno fiscale 2024, il Rapporto Trimestrale del primo trimestre 2025 e i materiali per la proxy
  • Include disposizioni complete di indennizzo per amministratori e dirigenti secondo la legge del Delaware
  • L'azienda mantiene una copertura assicurativa per la responsabilità di amministratori e dirigenti

La registrazione comprende impegni standard riguardanti le modifiche post-entrata in vigore e la rimozione dei titoli non venduti. L'opinione legale e il consenso di PricewaterhouseCoopers LLP sono allegati come documenti esibiti. Questa dichiarazione di registrazione consente a Zimmer Biomet di offrire compensi basati su azioni ai dipendenti secondo il suo piano di incentivi.

Zimmer Biomet Holdings ha presentado un Formulario S-8 para registrar valores bajo su Plan de Incentivos de Acciones 2009. La compañía, un gran emisor acelerado con sede en Warsaw, Indiana, está registrando acciones adicionales para beneficios a empleados.

Los aspectos clave de la presentación incluyen:

  • La registración cubre el Plan de Incentivos de Acciones 2009 enmendado y reformulado (referenciado en el 8-K presentado el 3 de junio de 2025)
  • La presentación incorpora por referencia varios documentos, incluyendo el Informe Anual para el año fiscal 2024, el Informe Trimestral del primer trimestre de 2025 y materiales para la junta de accionistas
  • Incluye disposiciones integrales de indemnización para directores y funcionarios bajo la ley de Delaware
  • La compañía mantiene cobertura de seguro de responsabilidad para directores y funcionarios

La presentación incluye compromisos estándar respecto a enmiendas posteriores a la vigencia y la eliminación de valores no vendidos. La opinión legal y el consentimiento de PricewaterhouseCoopers LLP están presentados como anexos. Esta declaración de registro permite a Zimmer Biomet ofrecer compensación basada en acciones a empleados bajo su plan de incentivos.

Zimmer Biomet Holdings는 2009년 주식 인센티브 계획에 따라 증권을 등록하기 위해 Form S-8을 제출했습니다. 인디애나 주 워소에 본사를 둔 대규모 가속 신고자인 이 회사는 직원 복지 목적으로 추가 주식을 등록하고 있습니다.

신고서의 주요 내용은 다음과 같습니다:

  • 등록은 수정 및 재작성된 2009년 주식 인센티브 계획을 포함하며(2025년 6월 3일 제출된 8-K 문서 참조)
  • 연례 보고서(FY2024), 1분기 분기 보고서(Q1 2025), 주주총회 자료 등 여러 문서를 참조로 포함
  • 델라웨어 법률에 따른 이사 및 임원에 대한 포괄적 면책 조항 포함
  • 회사는 이사 및 임원 책임 보험을 유지하고 있음

신고서에는 발효 후 수정 및 미판매 증권 제거에 관한 표준 약속이 포함되어 있습니다. PricewaterhouseCoopers LLP의 법률 의견서 및 동의서가 첨부되어 있습니다. 이 등록 서류는 Zimmer Biomet가 인센티브 계획에 따라 직원에게 주식 기반 보상을 제공할 수 있도록 합니다.

Zimmer Biomet Holdings a déposé un formulaire S-8 pour enregistrer des titres dans le cadre de son Plan d'Incitation en Actions 2009. La société, un grand déposant accéléré dont le siège est à Warsaw, Indiana, enregistre des actions supplémentaires pour les avantages destinés aux employés.

Les points clés du dépôt comprennent :

  • L'enregistrement couvre le Plan d'Incitation en Actions 2009 modifié et reformulé (référencé dans le formulaire 8-K déposé le 3 juin 2025)
  • Le dépôt incorpore par référence plusieurs documents, notamment le rapport annuel pour l'exercice 2024, le rapport trimestriel du premier trimestre 2025 et les documents de procuration
  • Comprend des dispositions complètes d'indemnisation pour les administrateurs et dirigeants selon la loi du Delaware
  • La société maintient une assurance responsabilité pour les administrateurs et dirigeants

Le dépôt inclut des engagements standard concernant les amendements postérieurs à l'entrée en vigueur et la suppression des titres invendus. L'avis juridique et le consentement de PricewaterhouseCoopers LLP sont déposés en tant que pièces jointes. Cette déclaration d'enregistrement permet à Zimmer Biomet d'offrir une rémunération basée sur des actions à ses employés dans le cadre de son plan d'incitation.

Zimmer Biomet Holdings hat ein Formular S-8 eingereicht, um Wertpapiere im Rahmen seines Aktienanreizplans von 2009 zu registrieren. Das Unternehmen, ein großer beschleunigter Melder mit Hauptsitz in Warsaw, Indiana, registriert zusätzliche Aktien für Mitarbeitervergütungen.

Wesentliche Aspekte der Einreichung umfassen:

  • Die Registrierung umfasst den geänderten und neu gefassten Aktienanreizplan von 2009 (verweist auf den am 3. Juni 2025 eingereichten 8-K-Bericht)
  • Die Einreichung bezieht sich auf mehrere Dokumente, darunter den Jahresbericht für das Geschäftsjahr 2024, den Quartalsbericht für Q1 2025 und Proxy-Materialien
  • Umfasst umfassende Entschädigungsbestimmungen für Direktoren und Führungskräfte gemäß dem Recht von Delaware
  • Das Unternehmen unterhält eine Haftpflichtversicherung für Direktoren und Führungskräfte

Die Einreichung enthält Standardverpflichtungen bezüglich nachwirkender Änderungen und der Entfernung unverkaufter Wertpapiere. Die Rechtsmeinung und Zustimmung von PricewaterhouseCoopers LLP sind als Anlagen eingereicht. Diese Registrierung ermöglicht es Zimmer Biomet, aktienbasierte Vergütungen an Mitarbeiter im Rahmen seines Anreizplans anzubieten.

Positive
  • Zimmer Biomet has amended and restated its 2009 Stock Incentive Plan, indicating continued commitment to employee equity compensation and alignment with shareholder interests
  • The company maintains comprehensive director and officer liability insurance and indemnification agreements, helping attract and retain top talent in leadership positions
Negative
  • None.

Zimmer Biomet Holdings ha presentato un Modulo S-8 per registrare titoli nell'ambito del suo Piano di Incentivi Azionari 2009. L'azienda, un grande emittente accelerato con sede a Warsaw, Indiana, sta registrando azioni aggiuntive per benefici destinati ai dipendenti.

Gli aspetti principali della registrazione includono:

  • La registrazione riguarda il Piano di Incentivi Azionari 2009 modificato e aggiornato (citato nel modulo 8-K presentato il 3 giugno 2025)
  • La documentazione fa riferimento a vari documenti, tra cui il Rapporto Annuale per l'anno fiscale 2024, il Rapporto Trimestrale del primo trimestre 2025 e i materiali per la proxy
  • Include disposizioni complete di indennizzo per amministratori e dirigenti secondo la legge del Delaware
  • L'azienda mantiene una copertura assicurativa per la responsabilità di amministratori e dirigenti

La registrazione comprende impegni standard riguardanti le modifiche post-entrata in vigore e la rimozione dei titoli non venduti. L'opinione legale e il consenso di PricewaterhouseCoopers LLP sono allegati come documenti esibiti. Questa dichiarazione di registrazione consente a Zimmer Biomet di offrire compensi basati su azioni ai dipendenti secondo il suo piano di incentivi.

Zimmer Biomet Holdings ha presentado un Formulario S-8 para registrar valores bajo su Plan de Incentivos de Acciones 2009. La compañía, un gran emisor acelerado con sede en Warsaw, Indiana, está registrando acciones adicionales para beneficios a empleados.

Los aspectos clave de la presentación incluyen:

  • La registración cubre el Plan de Incentivos de Acciones 2009 enmendado y reformulado (referenciado en el 8-K presentado el 3 de junio de 2025)
  • La presentación incorpora por referencia varios documentos, incluyendo el Informe Anual para el año fiscal 2024, el Informe Trimestral del primer trimestre de 2025 y materiales para la junta de accionistas
  • Incluye disposiciones integrales de indemnización para directores y funcionarios bajo la ley de Delaware
  • La compañía mantiene cobertura de seguro de responsabilidad para directores y funcionarios

La presentación incluye compromisos estándar respecto a enmiendas posteriores a la vigencia y la eliminación de valores no vendidos. La opinión legal y el consentimiento de PricewaterhouseCoopers LLP están presentados como anexos. Esta declaración de registro permite a Zimmer Biomet ofrecer compensación basada en acciones a empleados bajo su plan de incentivos.

Zimmer Biomet Holdings는 2009년 주식 인센티브 계획에 따라 증권을 등록하기 위해 Form S-8을 제출했습니다. 인디애나 주 워소에 본사를 둔 대규모 가속 신고자인 이 회사는 직원 복지 목적으로 추가 주식을 등록하고 있습니다.

신고서의 주요 내용은 다음과 같습니다:

  • 등록은 수정 및 재작성된 2009년 주식 인센티브 계획을 포함하며(2025년 6월 3일 제출된 8-K 문서 참조)
  • 연례 보고서(FY2024), 1분기 분기 보고서(Q1 2025), 주주총회 자료 등 여러 문서를 참조로 포함
  • 델라웨어 법률에 따른 이사 및 임원에 대한 포괄적 면책 조항 포함
  • 회사는 이사 및 임원 책임 보험을 유지하고 있음

신고서에는 발효 후 수정 및 미판매 증권 제거에 관한 표준 약속이 포함되어 있습니다. PricewaterhouseCoopers LLP의 법률 의견서 및 동의서가 첨부되어 있습니다. 이 등록 서류는 Zimmer Biomet가 인센티브 계획에 따라 직원에게 주식 기반 보상을 제공할 수 있도록 합니다.

Zimmer Biomet Holdings a déposé un formulaire S-8 pour enregistrer des titres dans le cadre de son Plan d'Incitation en Actions 2009. La société, un grand déposant accéléré dont le siège est à Warsaw, Indiana, enregistre des actions supplémentaires pour les avantages destinés aux employés.

Les points clés du dépôt comprennent :

  • L'enregistrement couvre le Plan d'Incitation en Actions 2009 modifié et reformulé (référencé dans le formulaire 8-K déposé le 3 juin 2025)
  • Le dépôt incorpore par référence plusieurs documents, notamment le rapport annuel pour l'exercice 2024, le rapport trimestriel du premier trimestre 2025 et les documents de procuration
  • Comprend des dispositions complètes d'indemnisation pour les administrateurs et dirigeants selon la loi du Delaware
  • La société maintient une assurance responsabilité pour les administrateurs et dirigeants

Le dépôt inclut des engagements standard concernant les amendements postérieurs à l'entrée en vigueur et la suppression des titres invendus. L'avis juridique et le consentement de PricewaterhouseCoopers LLP sont déposés en tant que pièces jointes. Cette déclaration d'enregistrement permet à Zimmer Biomet d'offrir une rémunération basée sur des actions à ses employés dans le cadre de son plan d'incitation.

Zimmer Biomet Holdings hat ein Formular S-8 eingereicht, um Wertpapiere im Rahmen seines Aktienanreizplans von 2009 zu registrieren. Das Unternehmen, ein großer beschleunigter Melder mit Hauptsitz in Warsaw, Indiana, registriert zusätzliche Aktien für Mitarbeitervergütungen.

Wesentliche Aspekte der Einreichung umfassen:

  • Die Registrierung umfasst den geänderten und neu gefassten Aktienanreizplan von 2009 (verweist auf den am 3. Juni 2025 eingereichten 8-K-Bericht)
  • Die Einreichung bezieht sich auf mehrere Dokumente, darunter den Jahresbericht für das Geschäftsjahr 2024, den Quartalsbericht für Q1 2025 und Proxy-Materialien
  • Umfasst umfassende Entschädigungsbestimmungen für Direktoren und Führungskräfte gemäß dem Recht von Delaware
  • Das Unternehmen unterhält eine Haftpflichtversicherung für Direktoren und Führungskräfte

Die Einreichung enthält Standardverpflichtungen bezüglich nachwirkender Änderungen und der Entfernung unverkaufter Wertpapiere. Die Rechtsmeinung und Zustimmung von PricewaterhouseCoopers LLP sind als Anlagen eingereicht. Diese Registrierung ermöglicht es Zimmer Biomet, aktienbasierte Vergütungen an Mitarbeiter im Rahmen seines Anreizplans anzubieten.

As filed with the Securities and Exchange Commission on June 20, 2025

Registration No. 333-    

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

ZIMMER BIOMET HOLDINGS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   13-4151777

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

345 East Main Street

Warsaw, Indiana 46580

(Address of Principal Executive Offices)

 

 

ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN

(Full Title of the Plan)

 

 

Chad F. Phipps

Senior Vice President, General Counsel and Secretary

Zimmer Biomet Holdings, Inc.

345 East Main Street

Warsaw, Indiana 46580

(Name and address of agent for service)

(574) 373-3333

(Telephone number, including area code, of agent for service)

Copy to:

Juliano Banuelos, Esq.

Orrick, Herrington & Sutcliffe LLP

405 Howard Street

San Francisco, California 94105-2669

(415) 773-5700

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

Item 1. Plan Information.

Information required by this Item 1 to be contained in the Section 10(a) prospectus is omitted from this registration statement on Form S-8 (the “Registration Statement”) in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

Item 2. Registrant Information and Employee Plan Annual Information.

Information required by this Item 2 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference

The following documents filed by Zimmer Biomet Holdings, Inc. (the “Registrant”) with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

 

  (a)

The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (File No. 001-16407) filed with the Commission on February 25, 2025;

 

  (b)

The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December  31, 2024 from its Definitive Proxy Statement on Schedule 14A (File No. 001-16407) filed with the Commission on April 14, 2025;

 

  (c)

The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 (File No. 001-16407) filed with the Commission on May 5, 2025;

 

  (d)

All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and

 

  (e)

The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 10-12B, filed on March 26, 2001, including any amendment or report filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of the filing of such documents, except as to specific sections of such statements as set forth therein.


Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

Item 4. Description of Securities

Not applicable.

Item 5. Interests of Named Experts and Counsel

Not applicable.

Item 6. Indemnification of Directors and Officers

Section 145 of the Delaware General Corporation Law (the “DGCL”) provides that a corporation may indemnify any current or former director, officer, employee or agent against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with civil, criminal, administrative or investigative actions, suits or proceedings, other than a derivative action by or in the right of the corporation, if the director, officer, employee or agent acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if he or she had no reasonable cause to believe his or her conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses incurred in connection with the defense or settlement of such actions, and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by any by-law, agreement, vote of stockholders or disinterested directors or otherwise.

The Registrant’s Restated Certificate of Incorporation provides that each person who was or is made a party or is threatened to be made a party to or is involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person, or a person of whom such person is the legal representative, is or was a director or officer of the Registrant or, while a director or officer of the Registrant, is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, will be indemnified and held harmless by the Registrant to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended to provide broader indemnification rights than authorized prior to such amendment. The Registrant will indemnify such persons against the expenses, liabilities and loss, including attorneys’ fees, judgments, fines and amounts paid in settlement, reasonably incurred by the person in connection with the action, suit or proceeding if the following standards are met:

 

   

the person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the Registrant’s best interests, and

 

   

with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

Section 145 of the DGCL also permits a corporation to pay expenses of defense incurred by a director or officer in defending any civil, criminal, administrative or investigative action, suit or proceeding in advance of the final disposition of such action, suit or proceeding upon receipt (in the case of a current director or officer) of an undertaking to repay all amounts advanced if it is ultimately determined that such director or officer is not entitled to be indemnified by the corporation. The Restated Certificate of Incorporation contains such a provision.


Such rights are not exclusive of any other right which any person may have or thereafter acquire under any statute, any provision of the Restated Certificate of Incorporation or the Registrant’s Restated Bylaws, or any agreement, vote of stockholders or disinterested directors or otherwise. The Registrant’s Restated Certificate of Incorporation also specifically authorizes the Registrant to maintain insurance and to grant similar indemnification rights to its employees or agents.

The Registrant has provided, consistent with the DGCL, in its Restated Certificate of Incorporation that a director of the Registrant shall not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

 

   

any breach of the director’s duty of loyalty to the Registrant or its stockholders;

 

   

acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

 

   

any transactions from which the director derived an improper personal benefit; or

 

   

any matter in respect of which the director would be liable under Section 174 of the DGCL.

Neither the amendment nor repeal of such provision will eliminate or reduce the effect of such provision in respect of any matter occurring, or any cause of action, suit or claim that, but for such provision, would accrue or arise prior to such amendment or repeal.

The Registrant has entered into indemnification agreements with its directors and executive officers providing for mandatory indemnification and advancement of expenses to the fullest extent permitted by applicable law.

In addition, the Registrant has a directors’ and officers’ liability policy that insures against certain liabilities, including liabilities under the Securities Act, subject to applicable retentions.

Item 7. Exemption From Registration Claimed

Not applicable.

Item 8. Exhibits

 

Exhibit Number

 

Description

  5.1*   Opinion of Orrick, Herrington & Sutcliffe LLP.
 23.1*   Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.
 23.2*   Consent of Orrick, Herrington & Sutcliffe LLP (filed as part of Exhibit 5.1 to this Registration Statement).
 24.1*   Powers of Attorney (filed as part of signature page of this Registration Statement).
 99.1   Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed June 3, 2025).
107*   Filing Fee Table.

 

*

Filed herewith.


Item 9. Undertakings

 

a.

The undersigned Registrant hereby undertakes:

 

  (1)

To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

 

  (i)

To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

  (ii)

To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

 

  (iii)

To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by such paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

 

  (2)

That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

  (3)

To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

b.

The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

c.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereby, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Warsaw, State of Indiana on the 20th day of June 2025.

 

ZIMMER BIOMET HOLDINGS, INC.

(Registrant)

By   /s/ Ivan Tornos
 

Ivan Tornos

President and Chief Executive Officer

(Principal Executive Officer)

POWER OF ATTORNEY

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in their respective capacities and on the respective dates indicated opposite their names. Each person whose signature appears below hereby authorizes each of Ivan Tornos, Suketu Upadhyay and Chad Phipps, each with full power of substitution, to execute in the name and on behalf of such person any amendment (including any post-effective amendment) to this Registration Statement and to file the same, with exhibits thereto, and other documents in connection therewith, making such changes in this Registration Statement as the Registrant deems appropriate, and appoints each of Ivan Tornos, Suketu Upadhyay and Chad Phipps, each with full power of substitution, attorney-in-fact to sign any amendment (including any post-effective amendment) to this Registration Statement and to file the same, with exhibits thereto, and other documents in connection therewith.

 

Signature

  

Title

 

Date

/s/ Ivan Tornos

Ivan Tornos

  

President, Chief Executive Officer and Director

(Principal Executive Officer)

  June 20, 2025

/s/ Suketu Upadhyay

Suketu Upadhyay

  

Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain

(Principal Financial Officer)

  June 20, 2025

/s/ Paul Stellato

Paul Stellato

  

Vice President, Controller and Chief Accounting Officer

(Principal Accounting Officer)

  June 20, 2025

/s/ Betsy Bernard

Betsy Bernard

   Director   June 20, 2025


Signature

  

Title

 

Date

/s/ Michael Farrell

Michael Farrell

   Director   June 20, 2025

/s/ Robert Hagemann

Robert Hagemann

   Director   June 20, 2025

/s/ Arthur Higgins

Arthur Higgins

   Director   June 20, 2025

/s/ Maria Teresa Hilado

Maria Teresa Hilado

   Director   June 20, 2025

/s/ Syed Jafry

Syed Jafry

   Director   June 20, 2025

/s/ Sreelakshmi Kolli

Sreelakshmi Kolli

   Director   June 20, 2025

/s/ Devdatt Kurdikar

Devdatt Kurdikar

   Director   June 20, 2025

/s/ Louis A. Shapiro

Louis A. Shapiro

   Director   June 20, 2025
Zimmer Biomet

NYSE:ZBH

ZBH Rankings

ZBH Latest News

ZBH Stock Data

18.05B
197.53M
0.2%
93.68%
3.54%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WARSAW